Betulin inhibits titanium particle-induced osteolysis and attenuates RANKL-associated osteoclastogenesis by suppressing the MAPK pathway
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Wear particle-induced aseptic loosening is an important factor compromising the long-term success of total joint replacement. It is often associated with osteolysis and inflammatory cellular responses within the joint. Betulin, a pentacyclic triterpenoid, promotes osteoblast differentiation and suppresses osteoclast formation. This study aimed to explore the therapeutic effect of betulin on aseptic loosening induced by wear particles and its underlying mechanism. A mouse calvarial model was used to study the effects of betulin on titanium particle-induced osteolysis in vivo. RAW264.7 murine macrophages were used to analyze titanium particle-induced inflammation and receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis in vitro. In mice with calvarial osteolysis induced by titanium particles, betulin treatment reduced the resorption pits and inhibited the expression of osteoclast-specific genes and inflammation-related genes. In RAW264.7 murine macrophages, betulin treatment inhibited the inflammatory response induced by particles and reduced RANKL-associated osteoclastogenesis by suppressing the mitogen-activated protein kinase (MAPK) pathway. These results indicate that betulin can inhibit titanium particle-induced osteolysis, an ability that is likely associated with reduced particle-induced inflammation and osteoclast activation. Based on these findings, betulin is proposed as a potential therapeutic candidate to mitigate wear particle-induced aseptic loosening.
Fields of Study & Subjects
Orthopaedic implants and arthroplasty
Bone Metabolism and Diseases
Titanium Alloys Microstructure and Properties
Publication details
- Journal / source
- European Journal of Pharmacology
- Volume
- 1021
- Pages
- 178828–178828
- Publication date
- 28 March 2026
- Language
- EN